EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dolutegravir Inhibits Autophagy In Vitro in a Mouse Blood–Brain Barrier Model

Chang Huang iD, Qing Rui Qu, Reina Bendayan

The FASEB Journal · 2025

DOI: 10.1096/fj.202500568rr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Chang Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Pyridones, Oxazines, Piperazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Government | Canadian Institutes of Health Research (CIHR), Ontario HIV Treatment Network (OHTN), Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the effectiveness and tolerability of antiretroviral therapy (ART) in treating HIV infection, integrase strand transfer inhibitors, particularly dolutegravir (DTG)‐based ART, have been associated with various brain complications. Our research group has previously reported that DTG disrupts the blood–brain barrier (BBB) by inducing endoplasmic reticulum (ER) stress. To further understand DTG‐associated toxicity, this follow‐up study assessed autophagy dysfunction, a critical process that is closely linked to ER stress, using primary cultures of mouse brain microvascular endothelial cells as a robust BBB rodent model. We demonstrated that DTG exposure at therapeutically relevant concentrations significantly increased Sqstm/p62, LC3B‐I and LC3B‐II protein expression, and downregulated autophagy‐related genes Ulk1 and Atg14, suggesting an autophagy inhibition as a result of DTG treatment. This study provides new insights into the toxicological mechanisms of DTG and pathogenesis of DTG‐associated brain complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood-Brain BarrierPyridonesOxazinesPiperazinesAutophagyHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsAnimalsMiceEndothelial CellsCells, CulturedEndoplasmic Reticulum StressMice, Inbred C57BLDolutegravir

Substanzen

PyridonesOxazinesPiperazinesHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsDolutegravir

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Chang Huang

Förderung

  • Canadian Government | Canadian Institutes of Health Research (CIHR)
  • Ontario HIV Treatment Network (OHTN)
  • Canadian Institutes of Health Research

Zitieren

APA

Huang, C., Qu, Q. R., & Bendayan, R. (2025). Dolutegravir Inhibits Autophagy In Vitro in a Mouse Blood–Brain Barrier Model. The FASEB Journal. https://doi.org/10.1096/fj.202500568rr

Vancouver

Huang C, Qu QR, Bendayan R. Dolutegravir Inhibits Autophagy In Vitro in a Mouse Blood–Brain Barrier Model. The FASEB Journal. 2025. doi:10.1096/fj.202500568rr

BibTeX
@article{Huang2025,
  author = {Huang, Chang and Qu, Qing Rui and Bendayan, Reina},
  title = {Dolutegravir Inhibits Autophagy In Vitro in a Mouse Blood–Brain Barrier Model},
  journal = {The FASEB Journal},
  year = {2025},
  doi = {10.1096/fj.202500568rr}
}
Kostenlos starten →